S-531011

DRUG3 trials

Sponsors

Shionogi, National Cancer Center Hospital East, M.D. Anderson Cancer Center

Conditions

Metastatic Colorectal CancerMetastatic Colorectal NeoplasmsMicrosatellite Stable / Proficient Mismatch Repair Colorectal CancerPhase IIRadScopalS-531011Solid Tumors

Phase 1

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

RecruitingNCT05101070

ShionogiSolid Tumors

Start: 2022-05-30End: 2028-05-31Target: 282Updated: 2026-03-18

A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

Not yet recruitingNCT07591597

National Cancer Center Hospital EastMetastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer

Start: 2026-05-01End: 2029-05-01Target: 68Updated: 2026-05-18

Phase 2

Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer

WithdrawnNCT07720115

M.D. Anderson Cancer CenterMetastatic Colorectal Cancer, Phase II, RadScopal +1

Start: 2026-08-12End: 2026-09-04Updated: 2026-09-11

Related Papers

Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2025-05-28